Un characterized protein C22orf46P: A potential drug target and biomarker

Target Name: C22orf46P

NCBI ID: G79640

C22orf46P

Un characterized protein C22orf46P: A potential drug target and biomarker

Abstract:

C22orf46P is a gene encoding a protein of unknown function in the human body. It has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This article aims to provide an overview of C22orf46P, its potential drug target status, and its potential as a biomarker for disease diagnosis and treatment.

Introduction:

C22orf46P is a gene located on chromosome 22q12 in the human body. It encodes a protein of unknown function, which has been named as C22orf46P. The protein is expressed in various tissues and cells of the body and is involved in various cellular processes. The function of C22orf46P is not well understood, and it is potential drug target and biomarker for various diseases.

Potential Drug Target:

C22orf46P has been identified as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its potential as a drug target is based on its unique structure and its involvement in various cellular processes.

The protein C22orf46P is a glycoprotein with four transmembrane domains and a cytoplasmic tail. It has a molecular weight of approximately 41 kDa and contains several potential drug target sites, including a potential N-terminal glycylation site, a potential tyrosine kinase-like activity, and a potential G-protein-coupled receptor (GPCR) receptor.

The N-terminal glycylation site is a potential target for small molecules, such as inhibitors, that can modulate the activity of C22orf46P. The tyrosine kinase-like activity of C22orf46P is also a potential target for small molecules that can modulate the activity of C22orf46P. The G-protein-coupled receptor (GPCR) receptor is a potential target for drugs that can modulate the activity of C22orf46P.

Potential Biomarker:

C22orf46P has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its potential as a biomarker is based on its expression and its involvement in various cellular processes.

The protein C22orf46P is expressed in various tissues and cells of the body, including the brain, pancreas, and heart. It is also involved in various cellular processes, including cell signaling, cell adhesion, and cell migration. Therefore, its expression level can be used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Conclusion:

C22orf46P is a gene encoding a protein of unknown function in the human body. Its potential as a drug target and biomarker for various diseases has been identified based on its unique structure and its involvement in various cellular processes. Further research is needed to fully understand the function of C22orf46P and its potential as a drug target and biomarker for various diseases.

Protein Name: Chromosome 22 Putative Open Reading Frame 46, Pseudogene

The "C22orf46P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C22orf46P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets